Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: Interactions and the risk of hospitalization for gastrointestinal bleeding

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 5, 2008, Pages 581-588

  Schelleman, H ^a   Bilker, W B ^a   Brensinger, C M ^a   Han, X ^a   Kimmel, S E ^a   Hennessy, S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFALEXIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; FLUCONAZOLE; GATIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PARACETAMOL; PREDNISONE; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE CONTROL STUDY; CELLULITIS; CHRONIC DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DRUG METABOLISM; FEMALE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAID; PNEUMONIA; PRIORITY JOURNAL; RISK; STATISTICAL ANALYSIS; THROMBOEMBOLISM; URINARY TRACT INFECTION; VAGINA CANDIDIASIS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; ANTIFUNGAL AGENTS; AZOLES; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FLUOROQUINOLONES; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK; SULFONAMIDES; WARFARIN;

EID: 54249118120     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.150     Document Type: Article

References (35)

1. Bungard, T.J., Ghali, W.A., Teo, K.K., McAlister, F.A. & Tsuyuki, R.T. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med. 160, 41-46 (2000).
2. Gullov, A.L., Koefoed, B.G. & Petersen, P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch. Intern. Med. 159, 1322-1328 (1999).
3. Breckenridge, A.M. Interindividual differences in the response to oral anticoagulants. Drugs 14, 367-375 (1977).
4. MICROMEDIX 〈http://www.thomsonhc.com/hcs/librarian〉 Accessed 10 August 2007.
5. Drug Facts & Comparisons 4.0 〈http://www.factsandcomparisons. com〉 Accessed 7 July 2007.
6. Holbrook, A.M. et al. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165, 1095-1106 (2005).
7. Haber, L.T., Maier, A., Gentry, P.R., Clewell, H.J. & Dourson, M.L. Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Toxicol. Pharmacol. 35, 177-197 (2002).
8. Hochman, R., Clark, J., Rolla, A., Thomas, S., Kaldany, A. & D'Elia, J.A. Bleeding in patients with infections. Are antibiotics helping or hurting? Arch. Intern. Med. 142, 1440-1442 (1982).
9. Rindone, J.P., Kelley, C.L., Jones, W.N. & Garewal, H.S. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin. Clin. Pharm. 10, 136-138 (1991).
10. Bianco, T.M., Bussey, H.I., Farnett, L.E., Linn, W.D., Roush, M.K. & Wong, Y.W. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 12, 435-439 (1992).
11. Yamreudeewong, W., Lower, D.L., Kilpatrick, D.M., Enlow, A.M., Burrows, M.M. & Greenwood, M.C. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. Pharmacotherapy 23, 333-338 (2003).
12. McCall, K.L., Scott, J.C. & Anderson, H.G. Retrospective evaluation of a possible interaction between warfarin and levofloxacin. Pharmacotherapy 25, 67-73 (2005).
13. Stroud, L.F., Mamdami, M.M., Kopp, A. & Bell, C.M. The safety of levofloxacin in elderly patients on warfarin. Am. J. Med. 118, 1417 (2005).
14. Israel, D.S. et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin. Infect. Dis. 22, 251-256 (1996).
15. Jolson, H.M., Tanner, L.A., Green, L. & Grasela, T.H. Jr. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch. Intern. Med. 151, 1003-1004 (1991).
16. Artymowicz, R.J., Cino, B.J., Rossi, J.G., Walker, J.L. & Moore, S. Possible interaction between gatifloxacin and warfarin. Am. J. Health Syst. Pharm. 59, 1205-1206 (2002).
17. Glasheen, J.J., Fugit, R.V. & Prochazka, A.V. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J. Gen. Intern. Med. 20, 653-656 (2005).
18. Harris, J.E. Interaction of dietary factors with oral anticoagulants: review and applications. J. Am. Diet. Assoc. 95, 580-584 (1995).
19. Hylek, E.M., Heiman, H., Skates, S.J., Sheehan, M.A. & Singer, D.E. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 279, 657-662 (1998).
20. Black, J.A. Diarrhoea, vitamin K, and warfarin. Lancet 344, 1373 (1994).
21. Hirsh, J., Fuster, V., Ansell, J. & Halperin, J.L.; American Heart Association/American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 41, 1633-1652 (2003).
22. Horn, J.R. & Hansten, P.D. Enhanced warfarin response and antibiotics. Pharmacy Times 70 (2004).
23. Penning-van Beest, F., Erkens, J., Petersen, K.U., Koelz, H.R. & Herings, R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur. J. Clin. Pharmacol. 61, 439-444 (2005).
24. Lipsky, J.J. Antibiotic-associated hypoprothrombinaemia. J. Antimicrob. Chemother. 21, 281-300 (1988).
25. Zhang, K., Young, C. & Berger, J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J. Manag. Care Pharm. 12, 640-648 (2006).
26. Gage, B.F. et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 151, 713-719 (2006).
27. Wysowski, D.K., Nourjah, P. & Swartz, L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167, 1414-1419 (2007).
28. Raiford, D.S., Perez Gutthann, S. & Garcia Rodriguez, L.A. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 7, 101-104 (1996).
29. Hamberg, A.K. et al. A PK/PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther. 81, 529-538 (2006).
30. Hennessy, S., Carson, J.L., Ray, W.A. & Strom, B.L. In Pharmacoepidemiology. 4th edn. (ed. Strom, B.L.) 281-294 (Wiley, Chichester, UK, 2005).
31. Medicare Payment Advisory Commission. Report to the Congress: New Approaches in Medicare. 2004.
32. Hennessy, S., Leonard, C.E., Palumbo, C.M., Newcomb, C. & Bilker, W.B. Quality of Medicaid and Medicare Data obtained through Centers for Medicare and Medicaid Services (CMS). Med. Care 45, 1216-1220 (2007).
33. Flanders, W.D. & Louv, W.C. The exposure odds ratio in nested case-control studies with competing risks. Am. J. Epidemiol. 124, 684-692 (1986).
34. Mittleman, M.A., Maclure, M. & Robins, J.M. Control sampling strategies for case-crossover studies: an assessment of relative efficiency. Am. J. Epidemiol. 142, 91-98 (1995).
35. Mickey, R.M. & Greenland, S. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 129, 125-137 (1989).